Evolution and Prognosis of Tricuspid and Mitral Regurgitation Following Cardiac Implantable Electronic Devices. A Systematic Review and Meta-analysis.

Tricuspid regurgitation cardiac resynchronization therapy conduction system pacing implantable cardioverter defibrillator leadless pacemaker mitral regurgitation pacemaker

Journal

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
ISSN: 1532-2092
Titre abrégé: Europace
Pays: England
ID NLM: 100883649

Informations de publication

Date de publication:
30 May 2024
Historique:
received: 22 03 2024
accepted: 23 05 2024
medline: 30 5 2024
pubmed: 30 5 2024
entrez: 30 5 2024
Statut: aheadofprint

Résumé

Significant changes in tricuspid regurgitation (TR) and mitral regurgitation (MR) post-cardiac implantable electronic devices (CIED) are increasingly recognized. However, uncertainty remains as to whether risk of CIED-associated TR and MR differs with right ventricular pacing (RVP) via CIED with trans-tricuspid RV leads, compared to cardiac resynchronization therapy (CRT), conduction system pacing (CSP), and leadless pacing (LP). Synthesize extant data on risk and prognosis of significant post-CIED TR and MR across pacing strategies. We searched PubMed, EMBASE, and Cochrane Library databases published until October 31st, 2023. Significant post-CIED TR and MR were defined as ≥ moderate. Fifty-seven TR studies (N=13,723 patients) and 90 MR studies (N =14,387 patients) were included. For all CIED, risk of post-CIED TR increased (pooled odds ratio (OR)=2.46 and 95% CI=1.88-3.22), while risk of post-CIED MR reduced (OR=0.74, 95% CI=0.58-0.94) after 12 and 6 months of median follow-up respectively. RVP via CIED with trans-tricuspid RV leads was associated with increased risk of post-CIED TR (OR=4.54, 95% CI=3.14-6.57) and post-CIED MR (OR=2.24, 95% CI=1.18-4.26). Binarily, CSP did not alter TR risk (OR=0.37, 95% CI=0.13-1.02), but significantly reduced MR (OR =0.15, 95% CI=0.03-0.62). CRT did not significantly change TR risk (OR=1.09, 95% CI=0.55-2.17), but significantly reduced MR with prevalence pre-CRT of 43%, decreasing post-CRT to 22% (OR =0.49, 95% CI=0.40-0.61). There was no significant association of LP with post-CIED TR (OR=1.15, 95% CI=0.83-1.59) or MR (OR=1.31, 95% CI=0.72-2.39). CIED-associated TR was independently predictive of all-cause mortality (pooled hazard ratio (HR)=1.64, 95% CI=1.40-1.90) after median of 53 months. MR persisting post-CRT independently predicted all-cause mortality (HR=2.00, 95% CI=1.57-2.55) after 38 months. Our findings suggest that, when possible, adoption of pacing strategies which avoid isolated trans-tricuspid RV leads may be beneficial in preventing incident or deteriorating atrioventricular valvular regurgitation and might reduce mortality.

Sections du résumé

BACKGROUND BACKGROUND
Significant changes in tricuspid regurgitation (TR) and mitral regurgitation (MR) post-cardiac implantable electronic devices (CIED) are increasingly recognized. However, uncertainty remains as to whether risk of CIED-associated TR and MR differs with right ventricular pacing (RVP) via CIED with trans-tricuspid RV leads, compared to cardiac resynchronization therapy (CRT), conduction system pacing (CSP), and leadless pacing (LP).
AIMS OBJECTIVE
Synthesize extant data on risk and prognosis of significant post-CIED TR and MR across pacing strategies.
METHODS METHODS
We searched PubMed, EMBASE, and Cochrane Library databases published until October 31st, 2023. Significant post-CIED TR and MR were defined as ≥ moderate.
RESULTS RESULTS
Fifty-seven TR studies (N=13,723 patients) and 90 MR studies (N =14,387 patients) were included. For all CIED, risk of post-CIED TR increased (pooled odds ratio (OR)=2.46 and 95% CI=1.88-3.22), while risk of post-CIED MR reduced (OR=0.74, 95% CI=0.58-0.94) after 12 and 6 months of median follow-up respectively. RVP via CIED with trans-tricuspid RV leads was associated with increased risk of post-CIED TR (OR=4.54, 95% CI=3.14-6.57) and post-CIED MR (OR=2.24, 95% CI=1.18-4.26). Binarily, CSP did not alter TR risk (OR=0.37, 95% CI=0.13-1.02), but significantly reduced MR (OR =0.15, 95% CI=0.03-0.62). CRT did not significantly change TR risk (OR=1.09, 95% CI=0.55-2.17), but significantly reduced MR with prevalence pre-CRT of 43%, decreasing post-CRT to 22% (OR =0.49, 95% CI=0.40-0.61). There was no significant association of LP with post-CIED TR (OR=1.15, 95% CI=0.83-1.59) or MR (OR=1.31, 95% CI=0.72-2.39). CIED-associated TR was independently predictive of all-cause mortality (pooled hazard ratio (HR)=1.64, 95% CI=1.40-1.90) after median of 53 months. MR persisting post-CRT independently predicted all-cause mortality (HR=2.00, 95% CI=1.57-2.55) after 38 months.
CONCLUSIONS CONCLUSIONS
Our findings suggest that, when possible, adoption of pacing strategies which avoid isolated trans-tricuspid RV leads may be beneficial in preventing incident or deteriorating atrioventricular valvular regurgitation and might reduce mortality.

Identifiants

pubmed: 38812433
pii: 7685069
doi: 10.1093/europace/euae143
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.

Auteurs

Matthew F Yuyun (MF)

VA Boston Healthcare System, Boston, USA.
Harvard Medical School, Boston, USA.
Boston University Chobanian and Avedisian School of Medicine, Boston, USA.

Jacob Joseph (J)

VA Boston Healthcare System, Boston, USA.
VA Providence Healthcare System, Providence, Rhode Island, USA.
Brown University, Providence, Rhode Island, USA.

Sebhat A Erqou (SA)

VA Providence Healthcare System, Providence, Rhode Island, USA.
Brown University, Providence, Rhode Island, USA.

Scott Kinlay (S)

VA Boston Healthcare System, Boston, USA.
Harvard Medical School, Boston, USA.
Boston University Chobanian and Avedisian School of Medicine, Boston, USA.
Brigham and Women's Hospital, Boston, USA.

Justin B Echouffo-Tcheugui (JB)

Johns Hopkins University School of Medicine, Baltimore, USA.

Adelqui O Peralta (AO)

VA Boston Healthcare System, Boston, USA.
Harvard Medical School, Boston, USA.
Boston University Chobanian and Avedisian School of Medicine, Boston, USA.

Peter S Hoffmeister (PS)

VA Boston Healthcare System, Boston, USA.
Harvard Medical School, Boston, USA.
Boston University Chobanian and Avedisian School of Medicine, Boston, USA.

William E Boden (WE)

VA Boston Healthcare System, Boston, USA.
Harvard Medical School, Boston, USA.
Boston University Chobanian and Avedisian School of Medicine, Boston, USA.

Hirad Yarmohammadi (H)

Department of Medicine, Columbia University, New York, USA.

David T Martin (DT)

Harvard Medical School, Boston, USA.
Brigham and Women's Hospital, Boston, USA.

Jagmeet P Singh (JP)

Harvard Medical School, Boston, USA.
Massachusetts General Hospital, Boston, USA.

Classifications MeSH